Mineralys Therapeutics announced positive topline results from its phase 2 Explore-CKD trial, in which lorundrostat lowered ...

Richard Lafayette, MD, FACP, explains why a REMS program is not required for the endothelin A receptor antagonist and how ...

Dysregulation of the alternative complement pathway, hallmarked by isolated reduction of the serum C3 fraction, is now recognized as an additional feature of lupus nephritis.

Researchers at the University of Tsukuba have developed a novel mouse model that allows them to induce dysfunction in only ...

A new study published in JAMA Network Open reveals significant concerns about Medicare Advantage (MA) marketing practices and their impact on patients with end-stage kidney disease (ESKD). The ...

Tacrolimus has previously shown antipruritic action in atopic dermatitis, so researchers decided to investigate it for uremic pruritus.